Frontier Biotech Teams Up with GSK for Exclusive RNA Therapy Licensing Agreement Frontier Biotech has entered a major exclusive licensing agreement with GSK for developing two innovative small interfering RNA therapies, marking a significant milestone.

Frontier Biotech Teams Up with GSK for Exclusive RNA Therapy Licensing Agreement #USA #Nanjing #GSK #RNA_Therapy #Frontier_Biotech

Ribo Life Science Achieves Successful Listing on Hong Kong Stock Exchange Global biotech firm Ribo Life Science successfully lists on the Hong Kong Stock Exchange, marking a pivotal milestone in RNA therapy.

Ribo Life Science Achieves Successful Listing on Hong Kong Stock Exchange #Hong_Kong #RNA_Therapy #Ribo_Life_Science

Lexogen Completes Large-Scale Next-Generation Sequencing Project with Ochre Bio Lexogen successfully finalizes a massive project generating genomic datasets from human primary hepatocytes, collaborating with Ochre Bio in advancing RNA-based therapies.

Lexogen Completes Large-Scale Next-Generation Sequencing Project with Ochre Bio #Vienna #Austria #RNA_Therapy #Lexogen #Ochre_Bio

CREATE Medicines: Revolutionizing Immunotherapy with RNA-Based Multi-Immune Programming CREATE Medicines is redefining immunotherapy through innovative RNA-based multi-immune programming, expanding treatment options and improving patient outcomes.

CREATE Medicines: Revolutionizing Immunotherapy with RNA-Based Multi-Immune Programming #USA #Cambridge #Immunotherapy #RNA_Therapy #CREATE_Medicines

Introducing Mina™: The First AI Agent for Lipid Nanoparticles Revolutionizing RNA Therapy Mina™, developed by Mana.bio, is the first AI agent specifically designed for lipid nanoparticles, enhancing RNA therapy research with predictive modeling.

Introducing Mina™: The First AI Agent for Lipid Nanoparticles Revolutionizing RNA Therapy #USA #Boston #Mana.bio #RNA_Therapy #Mina™

Quotient Sciences and CPI Collaborate on RNA Drug Development Venture Quotient Sciences and CPI have entered a joint venture to expedite RNA therapy development, integrating unique manufacturing and expertise to enhance clinical trial efficiency.

Quotient Sciences and CPI Collaborate on RNA Drug Development Venture #United_Kingdom #CPI #Nottingham #RNA_Therapy #Quotient_Sciences

Rznomics Partners with Eli Lilly to Pioneer RNA Editing Therapies for Hearing Loss Rznomics and Eli Lilly have signed a transformative agreement to develop RNA editing therapies aimed at treating sensorineural hearing loss, potentially worth over $1.3 billion.

Rznomics Partners with Eli Lilly to Pioneer RNA Editing Therapies for Hearing Loss #South_Korea #Rznomics #Seongnam #Eli_Lilly #RNA_Therapy

Wayfinder Biosciences and Daiichi Sankyo Join Forces for Innovative RNA-Targeting Therapies Wayfinder Biosciences teams up with Daiichi Sankyo to develop innovative RNA-targeting treatments for neurodegenerative diseases, promising new hope.

Wayfinder Biosciences and Daiichi Sankyo Join Forces for Innovative RNA-Targeting Therapies #USA #Seattle #Daiichi_Sankyo #Wayfinder_Biosciences #RNA_Therapy